Table 2 Summary of best response

From: Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

 

Number of patients (%) ( n =38)

Evaluable

35 (92)

 CR

—

 PR

—

 SD

12 (32)

95% CI

18–49

Median duration of SD (months)

2.6

 95% CI

2.6–2.8

 PD

23 (61)

95% CI

43–76

Not evaluable

3 (8)

Early deatha

1 (3)

Insufficient data

2 (5)

  1. Abbreviations: CI=confidence interval; CR=complete response; PD=progressive disease; PR=partial response; SD=stable disease.
  2. aDeath due to progressive disease.
Back to article page